Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
AIDS. 2010 Jul 31;24(12):1937-44. doi: 10.1097/QAD.0b013e32833b3282.
To assess the association between hormonal contraceptive use and HIV progression.
A retrospective analysis of 625 female HIV seroconverters from a Ugandan cohort study.
Multivariate Cox regression analyses incorporating time-varying hormonal contraceptive exposure were used to estimate the adjusted hazard ratios of death, and a composite outcome of AIDS or death, associated with hormonal contraceptive use. Sensitivity analyses included lagging hormonal contraceptive exposure, varying comparison groups, and separately assessing effects of oral and injectable contraceptives.
A total of 27.5% of women reported ever using hormonal contraception. Of 625 women, 104 (16.6%) died and 291 (46.6%) progressed to AIDS or death during observation. Time-varying hormonal contraceptive use was not associated with an increased hazard of death as compared with nonuse of hormonal contraception (adjusted hazard ratio 0.76, 95% confidence interval 0.41-1.39, P = 0.37), and was associated with a significantly reduced hazard of progression to AIDS or death (adjusted hazard ratio 0.70, 95% confidence interval 0.50-0.97, P = 0.03). None of the sensitivity analyses suggested an adverse effect of hormonal contraception on HIV progression.
Hormonal contraceptive use was not associated with faster progression to death, and was associated with a reduced hazard of progression to the composite outcome of AIDS or death.
评估激素避孕与 HIV 进展的关联。
对乌干达队列研究中的 625 名女性 HIV 血清转化者进行回顾性分析。
采用包含时变激素避孕暴露的多变量 Cox 回归分析,估计与激素避孕使用相关的死亡和 AIDS 或死亡复合结局的调整后危险比。敏感性分析包括滞后激素避孕暴露、改变对照组以及分别评估口服和注射避孕药的影响。
共有 27.5%的女性报告曾使用过激素避孕。在 625 名女性中,有 104 名(16.6%)死亡,291 名(46.6%)在观察期间进展为 AIDS 或死亡。与未使用激素避孕相比,时变激素避孕使用与死亡风险增加无关(调整后的危险比为 0.76,95%置信区间为 0.41-1.39,P=0.37),且与 AIDS 或死亡复合结局的风险降低显著相关(调整后的危险比为 0.70,95%置信区间为 0.50-0.97,P=0.03)。敏感性分析均未提示激素避孕对 HIV 进展有不利影响。
激素避孕使用与更快的死亡进展无关,且与 AIDS 或死亡复合结局的风险降低相关。